Recent developments highlight revenue growth in the Med Tech segment, FDA approvals for clinical studies, and ongoing margin pressures amid macroeconomic challenges.

• AngioDynamics’ stock rose 8.9% since the last earnings report, reflecting market interest in recent performance [N1].
• The company anticipates Med Tech products becoming the majority of revenue in fiscal 2027, indicating a strategic shift towards higher-growth segments [N2].
• Margin pressures persist despite Med Tech growth, with inflation and tariffs cited as key challenges [N3][N4].
• The company received FDA IDE approval for a NanoKnife feasibility study in benign prostate hyperplasia, supporting clinical development efforts [N8].
• Q4 2026 earnings call highlighted revenue growth and gross margin expansion in Med Tech, alongside a reported net loss [N5][N6][N7][N8].

The company’s Med Tech segment shows notable revenue growth driven by innovative platforms like Auryon and NanoKnife, which are gaining market traction. Expansion of product offerings and geographic penetration, combined with ongoing clinical and regulatory progress, support business development. The company’s liquidity position and operational scale provide a foundation for continued investment in R&D and selective business development opportunities. Recent news indicates management’s focus on Med Tech becoming the majority revenue contributor, reflecting strategic emphasis on higher-margin products [N2][N4][N6].

Despite revenue growth, AngioDynamics faces persistent margin pressures influenced by inflation, tariffs, and supply chain challenges. The company reported net losses for fiscal year 2026 and recent quarters, reflecting ongoing profitability challenges. Competitive pressures, pricing dynamics, and macroeconomic factors such as labor shortages and raw material costs may constrain margin expansion. Regulatory and reimbursement risks inherent in the medical device sector also pose challenges. The company’s reliance on a limited number of product lines for growth may increase vulnerability to market shifts or competitive advances [S2][N3][N4].

AngioDynamics’ moat is supported by its diversified product portfolio in specialized medical devices used in minimally invasive procedures, which require regulatory approvals and clinical validation. The company’s direct sales force in the U.S. and established distributor relationships internationally provide market access. Its ongoing investments in research and development, clinical studies, and regulatory pathways, such as FDA IDE approvals for new indications, contribute to product innovation and competitive positioning. However, the medical device industry is competitive with consolidation trends and pricing pressures, which may impact margins and market share [S2][N8].

• Macroeconomic and Supply Chain Risks: Inflation, tariffs, labor shortages, and supply chain disruptions impact manufacturing costs and product availability, potentially affecting margins and sales.
• Regulatory and Clinical Risks: The company’s products require regulatory approvals and clinical validation; delays or adverse outcomes in clinical studies or regulatory reviews could affect product launches and sales.
• Competitive and Pricing Pressure: Industry consolidation and competition from larger medical device companies may pressure pricing and market share, impacting revenue and profitability.
• Profitability Challenges: The company reported net losses and faces ongoing margin pressures, which may affect financial stability and investment capacity.

• AngioDynamics, Inc. is a diversified medical technology company focused on cardiovascular disease and cancer treatment devices used in minimally invasive, image-guided procedures [S2].
• The company designs, manufactures, and sells medical, surgical, and diagnostic devices primarily used by healthcare professionals such as interventional radiologists, cardiologists, vascular surgeons, urologists, oncologists, and critical care nurses [S2].
• Products include vascular access devices, peripheral vascular disease treatment devices, and oncology and surgical devices, many of which are disposable or temporarily implanted [S2].
• AngioDynamics operates two main segments: Med Tech and Med Device. Med Tech includes products like Auryon, thrombus management platforms (AlphaVac, AngioVac), and NanoKnife; Med Device includes Core, Venous, Ports, Microwave, and Oncology products [S2].
• For the nine months ended February 28, 2026, net sales increased 10.0% to $233.6 million, with Med Tech growing 19.1% and Med Device 3.2% [S2].
• Gross margin for the nine months ended February 28, 2026 was 54.9%, with Med Tech at 63.3% and Med Device at 47.6% [S2].
• The company reported a net loss of $36.7 million for fiscal year ended May 31, 2026, with basic and diluted EPS of -$0.88 [S1].
• Liquidity as of May 31, 2026 included $53.9 million in cash and equivalents, $16.3 million in current assets, and a current ratio of 2.19 and cash ratio of 0.91 [S1].
• AngioDynamics sells primarily in the United States through a direct sales force and internationally through distributors [S2].
• The company faces macroeconomic challenges including inflation, tariffs, labor shortages, supply chain issues, and regulatory risks [S2].
• Recent news highlights include AngioDynamics seeing Med Tech becoming the majority of revenue in fiscal 2027 and ongoing margin pressures despite growth [N2][N3][N4].
• The company received FDA IDE approval for a NanoKnife feasibility study in benign prostate hyperplasia, indicating ongoing clinical and regulatory activity [N8].
• Recent quarterly results showed revenue growth but also increased net losses and margin pressures, with management focusing on expanding product offerings and geographic presence [N5][N6][N7][N8].